Zoetis Inc. (LON: 0M3Q)

London flag London · Delayed Price · Currency is GBP · Price in USD
164.50
-0.64 (-0.39%)
Dec 23, 2024, 11:21 AM BST
-17.04%
Market Cap 59.15B
Revenue (ttm) 6.83B
Net Income (ttm) 1.81B
Shares Out n/a
EPS (ttm) 3.97
PE Ratio 32.63
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jan 21, 2025
Volume 4
Open 164.50
Previous Close 165.14
Day's Range 164.50 - 164.50
52-Week Range 151.44 - 201.92
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 14, 2025

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1952
Employees 14,100
Stock Exchange London Stock Exchange
Ticker Symbol 0M3Q
Full Company Profile

Financial Performance

In 2023, Zoetis's revenue was $8.54 billion, an increase of 5.74% compared to the previous year's $8.08 billion. Earnings were $2.34 billion, an increase of 10.88%.

Financial numbers in USD Financial Statements

News

Zoetis dips as FDA cites adverse events linked to canine pain therapy Librela

Zoetis (ZTS) stock falls as FDA notifies about adverse events in dogs treated with the company's pain therapy Librela. Read more here.

5 days ago - Seeking Alpha

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Zoetis (NYSE: ZTS) has outperformed the market over the past 10 years by 4.24% on an annualized basis producing an average annual return of 15.83%. Currently, Zoetis has a market capitalization of $8...

10 days ago - Benzinga

Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% ...

10 days ago - Business Wire

Zoetis: Are Competition And Price Increases A Cause For Concern?

Zoetis is the market leader in a growing industry, and the numbers are starting to show its dominance. Click here to read an analysis of ZTS stock now.

16 days ago - Seeking Alpha

The animal health industry is resilient, Zoetis CEO

Zoetis CEO Kristin Peck unpacks pet owners' concerns in caring for their beloved animals on 'The Claman Countdown.'

18 days ago - Fox Business

How do I get out of a lease for a Renault electric car battery?

Reader says it is unfair she would have to pay £2,000 to buy the battery in her Zoe, or £400 to have it removed I own an eight-year-old Renault Zoe and lease the battery for £50 a month from Mobilize ...

20 days ago - The Guardian

My Top 15 High-Growth Dividend Stocks For December 2024

The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and a...

21 days ago - Seeking Alpha

Zoetis: Healing Paws, Growing Profits

24 days ago - Seeking Alpha

Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)

Zoetis Inc. (NYSE:ZTS) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen San...

4 weeks ago - Seeking Alpha

Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, E...

4 weeks ago - Business Wire

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending...

5 weeks ago - Seeking Alpha

Zoetis: The Major Player in the $500B Pet Market You May Not Have Heard Of

The pet industry is growing fast and could reach a global market size of half a trillion dollars by 2032. This episode looks at why people bought more pets during COVID, the trend of treating pets lik...

5 weeks ago - After Earnings

Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

PARSIPPANY, N. J.--(BUSINESS WIRE)--ZOETIS APPOINTS JAMIE BRANNAN TO NEWLY CREATED CHIEF COMMERCIAL OFFICER ROLE.

6 weeks ago - Business Wire

Zoetis Q3: Strong Osteoarthritis Pain Franchise

I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA and S...

6 weeks ago - Seeking Alpha

Zoetis to Participate in Jefferies London Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executi...

6 weeks ago - Business Wire

Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript

Zoetis Inc. (NYSE:ZTS) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Er...

6 weeks ago - Seeking Alpha

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Fraud

LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("...

6 weeks ago - Accesswire

Zoetis raises annual forecasts on strong demand for pet treatments

Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.

7 weeks ago - Reuters

Zoetis Announces Third Quarter 2024 Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue a...

7 weeks ago - Business Wire

My Top 15 High-Growth Dividend Stocks For November 2024

The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% an...

7 weeks ago - Seeking Alpha

Zoetis Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("...

7 weeks ago - Accesswire

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("...

7 weeks ago - Accesswire

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certai...

7 weeks ago - Business Wire